Family Firm Inc. Has $405,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

Family Firm Inc. decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 3.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,577 shares of the healthcare product maker’s stock after selling 120 shares during the period. Family Firm Inc.’s holdings in Abbott Laboratories were worth $405,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Impax Asset Management Group plc grew its holdings in shares of Abbott Laboratories by 0.5% during the third quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock worth $63,573,000 after purchasing an additional 2,754 shares during the last quarter. United Bank boosted its holdings in shares of Abbott Laboratories by 1.8% during the 3rd quarter. United Bank now owns 27,284 shares of the healthcare product maker’s stock worth $3,111,000 after buying an additional 488 shares in the last quarter. Broderick Brian C raised its position in shares of Abbott Laboratories by 0.3% during the third quarter. Broderick Brian C now owns 115,876 shares of the healthcare product maker’s stock worth $13,211,000 after purchasing an additional 290 shares during the period. CIBC Asset Management Inc raised its position in shares of Abbott Laboratories by 2.2% during the third quarter. CIBC Asset Management Inc now owns 696,651 shares of the healthcare product maker’s stock worth $79,353,000 after purchasing an additional 14,708 shares during the period. Finally, Vectors Research Management LLC acquired a new position in shares of Abbott Laboratories during the third quarter worth approximately $1,642,000. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This represents a 1.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the transaction, the executive vice president now owns 74,381 shares in the company, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 in the last quarter. 0.47% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company raised their target price on Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, January 23rd. UBS Group raised their target price on Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Bank of America raised their price target on Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 10th. Argus raised Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Evercore ISI raised their price objective on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a report on Thursday, January 2nd. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $137.94.

Abbott Laboratories Stock Performance

NYSE ABT opened at $127.02 on Friday. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $141.23. The business’s 50-day moving average price is $127.16 and its 200 day moving average price is $119.38. The firm has a market cap of $220.29 billion, a P/E ratio of 16.60, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.86%. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.